|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aberle DR, Adams AM, Berg CD, Black WC,
Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks
JD; National Lung Screening Trial Research Team: Reduced
lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ujiie H, Kadota K, Chaft JE, Buitrago D,
Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, et al:
Solid predominant histologic subtype in resected stage I lung
adenocarcinoma is an independent predictor of early, extrathoracic,
multisite recurrence and of poor postrecurrence survival. J Clin
Oncol. 33:2877–2884. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Cancer Institute: Surveillance,
Epidemiology, and End Results Program. Cancer Stat Facts, Lung and
Bronchus Cancer. http://seer.cancer.gov/statfacts/html/lungb.html.
|
|
5
|
Ujiie H, Tomida M, Akiyama H, Nakajima Y,
Okada D, Yoshino N, Takiguchi Y and Tanzawa H: Serum hepatocyte
growth factor and interleukin-6 are effective prognostic markers
for non-small cell lung cancer. Anticancer Res. 32:3251–3258.
2012.PubMed/NCBI
|
|
6
|
Ujiie H, Lee D, Kato T and Yasufuku K:
Gene Signature. Molecular Targeted Therapy of Lung Cancer.
Takiguchi Y: Springer; Singapore, Singapore: pp. 279–292. 2017,
View Article : Google Scholar
|
|
7
|
Nakajima T, Zamel R, Anayama T, Kimura H,
Yoshino I, Keshavjee S and Yasufuku K: Ribonucleic acid microarray
analysis from lymph node samples obtained by endobronchial
ultrasonography-guided transbronchial needle aspiration. Ann Thorac
Surg. 94:2097–2101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato T, Wada H, Patel P, Hu HP, Lee D,
Ujiie H, Hirohashi K, Nakajima T, Sato M, Kaji M, et al:
Overexpression of KIF23 predicts clinical outcome in primary lung
cancer patients. Lung Cancer. 92:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chomez P, De Backer O, Bertrand M, De
Plaen E, Boon T and Lucas S: An overview of the MAGE gene family
with the identification of all human members of the family. Cancer
Res. 61:5544–5551. 2001.PubMed/NCBI
|
|
11
|
Simpson AJ, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weynants P, Lethé B, Brasseur F, Marchand
M and Boon T: Expression of mage genes by non-small-cell lung
carcinomas. Int J Cancer. 56:826–829. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mecklenburg I, Stratakis DF, Huber RM,
Häussinger K, Morresi-Hauf A, Riethmüller G and Kufer P: Detection
of melanoma antigen-A expression in sputum and bronchial lavage
fluid of patients with lung cancer. Chest. 125(Suppl): S164–S166.
2004. View Article : Google Scholar
|
|
14
|
Jheon S, Hyun DS, Lee SC, Yoon GS, Jeon
CH, Park JW, Park CK, Jung MH, Lee KD and Chang HK: Lung cancer
detection by a RT-nested PCR using MAGE A1 - 6 common primers. Lung
Cancer. 43:29–37. 2004. View Article : Google Scholar
|
|
15
|
Hutchinson TP: Patterns of melanoma
antigen-A expression in lung cancer patients. Chest. 128:1069–1070.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mecklenburg I, Sienel W, Schmid S,
Passlick B and Kufer P: A threshold of systemic MAGE-A gene
expression predicting survival in resected non-small cell lung
cancer. Clin Cancer Res. 23:1213–1219. 2017. View Article : Google Scholar
|
|
17
|
Vansteenkiste JF, Cho BC, Vanakesa T, De
Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J,
Nakayama H, et al: Efficacy of the MAGE-A3 cancer immunotherapeutic
as adjuvant therapy in patients with resected MAGE-A3-positive
non-small-cell lung cancer (MAGRIT): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 17:822–835. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pujol JL, Vansteenkiste JF, De Pas TM,
Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V,
Taylor P, et al: Safety and immunogenicity of MAGE-A3 cancer
immunotherapeutic with or without adjuvant chemotherapy in patients
with resected stage IB to III MAGE-A3-positive non-small-cell lung
cancer. J Thorac Oncol. 10:1458–1467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marcar L, Maclaine NJ, Hupp TR and Meek
DW: Mage-A cancer/testis antigens inhibit p53 function by blocking
its interaction with chromatin. Cancer Res. 70:10362–10370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peche LY, Scolz M, Ladelfa MF, Monte M and
Schneider C: MageA2 restrains cellular senescence by targeting the
function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ.
19:926–936. 2012. View Article : Google Scholar :
|
|
22
|
Gazzeri S, Brambilla E, Caron de Fromentel
C, Gouyer V, Moro D, Perron P, Berger F and Brambilla C: p53
genetic abnormalities and myc activation in human lung carcinoma.
Int J Cancer. 58:24–32. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoo SB, Chung JH, Lee HJ, Lee CT, Jheon S
and Sung SW: Epidermal growth factor receptor mutation and p53
overexpression during the multistage progression of small
adenocarcinoma of the lung. J Thorac Oncol. 5:964–969. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu H, Gao L, Li F, Song F, Yang X and
Kasabov N: Identifying overlapping mutated driver pathways by
constructing gene networks in cancer. BMC Bioinformatics. 16(Suppl
5): S32015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M and Kaji M: Overexpression of CDC20 predicts poor prognosis
in primary non-small cell lung cancer patients. J Surg Oncol.
106:423–430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M and Kaji M: Overexpression of KIAA0101 predicts poor
prognosis in primary lung cancer patients. Lung Cancer. 75:110–118.
2012. View Article : Google Scholar
|
|
28
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M, Kondo S and Kaji M: Overexpression of MAD2 predicts
clinical outcome in primary lung cancer patients. Lung Cancer.
74:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart. Fourth edition. WHO Classification of
Tumours. 7. WHO Publications Center; Albany, NY: 2015
|
|
30
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakajima T, Anayama T, Koike T, Waddell T,
Keshavjee S, Kimura H, Yoshino I and Yasufuku K: Simultaneous
isolation of total RNA, DNA, and protein using samples obtained by
EBUS-TBNA. J Bronchology Interv Pulmonol. 18:301–305. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
ImageScope viewing software: Leica
Biosystem Imaging, INC. http://www.leicabiosystems.com/pathology-imaging/aperio-epathology/integrate/imagescope/.
|
|
33
|
Rizzardi AE, Johnson AT, Vogel RI,
Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ and Schmechel
SC: Quantitative comparison of immunohistochemical staining
measured by digital image analysis versus pathologist visual
scoring. Diagn Pathol. 7:422012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nagashio R, Sato Y, Jiang SX, Ryuge S,
Kodera Y, Maeda T and Nakajima T: Detection of tumor-specific
autoantibodies in sera of patients with lung cancer. Lung Cancer.
62:364–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nagashio R, Sato Y, Matsumoto T, Kageyama
T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang SX and Okayasu
I: Expression of RACK1 is a novel biomarker in pulmonary
adenocarcinomas. Lung Cancer. 69:54–59. 2010. View Article : Google Scholar
|
|
36
|
Ujiie H, Kadota K, Nitadori JI, Aerts JG,
Woo KM, Sima CS, Travis WD, Jones DR, Krug LM and Adusumilli PS:
The tumoral and stromal immune microenvironment in malignant
pleural mesothelioma: A comprehensive analysis reveals prognostic
immune markers. Oncoimmunology. 4:e10092852015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cha YJ, Kim HR, Lee CY, Cho BC and Shim
HS: Clinicopathological and prognostic significance of programmed
cell death ligand-1 expression in lung adenocarcinoma and its
relationship with p53 status. Lung Cancer. 97:73–80. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shim HS, Kenudson M, Zheng Z, Liebers M,
Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS and Iafrate AJ:
Unique genetic and survival characteristics of invasive mucinous
adenocarcinoma of the lung. J Thorac Oncol. 10:1156–1162. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brattström D, Bergqvist M, Lamberg K,
Kraaz W, Scheibenflug L, Gustafsson G, Inganäs M, Wagenius G and
Brodin O: Complete sequence of p53 gene in 20 patients with lung
cancer: Comparison with chemosensitivity and immunohistochemistry.
Med Oncol. 15:255–261. 1998. View Article : Google Scholar
|
|
40
|
Peikert T, Specks U, Farver C, Erzurum SC
and Comhair SA: Melanoma antigen A4 is expressed in non-small cell
lung cancers and promotes apoptosis. Cancer Res. 66:4693–4700.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sakurai T, Itoh K, Higashitsuji H, Nagao
T, Nonoguchi K, Chiba T and Fujita J: A cleaved form of MAGE-A4
binds to Miz-1 and induces apoptosis in human cells. J Biol Chem.
279:15505–15514. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang B, O'Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
